Here’s how much pharma executives are paying for real-world data — and who they’re buying data from

CB Insights July 10, 2023
Deepashri Varadharajan

Real-world data (RWD) is transforming the drug R&D value chain.

RWD — an umbrella term for patient data mined from health records, insurance claims, clinical registries, genomic databases, and surveys of patient-reported outcomes — was initially used to collect evidence about a drug‘s post-market safety.

Today, these datasets are being used to match patients to the right trials, design study protocols, create simulated control arms in clinical trials, and identify promising drug targets.

Major pharma companies are actively evaluating and investing in RWD vendors. For example:

• Pfizer is working with startup Syapse on breast cancer data.
• GSK partnered with unicorn Tempus to speed up clinical trials and identify drug targets in oncology.
• Sanofi has worked with Evidation,...

Today's Sponsors

Today's Sponsor